Clinical Scorecard: FDA approves HPV immunotherapy for recurrent respiratory papillomatosis
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: FDA approves HPV immunotherapy for RRP
Key Mechanisms
Mechanisms or clinical associations described in the source article.
Target Population
Population described in the source article.
Care Setting
After surgical removal of visible papillomas, a trained health care professional administers Voceryq by intramuscular injection using the CELLECTRA 5PSP device.
Key Highlights
The FDA granted accelerated approval to Voceryq to reduce the frequency of surgical papilloma excisions in adults with RRP.
The approval is the first US approval of a plasmid DNA-based immunotherapy.
Evidence came from a multicenter, open-label, single-arm phase 1/2 study of 32 adults; the study had no concurrent control group.
Among 26 patients who had required at least 3 surgeries before treatment, 7 had no surgical papilloma excisions during the following 12 months.
Continued approval may depend on verification of clinical benefit in a confirmatory study.
Guideline-Based Recommendations
Diagnosis
The source provides no diagnostic recommendations.
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Adults with recurrent respiratory papillomatosis. The supporting study enrolled 32 adults who had required at least 2 surgical interventions during the preceding 12 months.
The FDA prescribing information recommends 4 intramuscular doses of 6.25 mg, 3 weeks apart, after surgical removal of visible papillomas. In the study efficacy population of 26 patients with at least 3 prior-year surgeries, 7 required no excisions in the subsequent 12 months; the median number of pretreatment surgeries was 4.5.
Clinical Best Practices
Remove visible papillomas surgically before starting treatment.
Use the CELLECTRA 5PSP device and have a trained health care professional administer each dose.
Observe injection sites for at least 30 minutes after each administration.
Avoid administration at sites with the listed implants or skin abnormalities.
Review of 88 studies found AI systems achieved high accuracy for identifying abnormal voices, but performance declined among higher-level laryngeal disorder classifications.
